Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours
The Journal of Pathology: Clinical Research · 2023-03 · 9 (2) · 89-99
DOI: 10.1002/cjp2.307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 19.12.2022. Verfasst von Yuehua Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR Ch…. Hauptthemen laut MEDLINE: Receptor, trkB, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Tropomyosin receptor kinase B (TrkB), a transmembrane receptor protein, has been found to play a pivotal role in neural development. This protein is encoded by the neurotrophic receptor tyrosine kinase 2 ( NTRK2 ) gene, and its abnormal activation caused by NTRK2 overexpression or fusion can contribute to tumour initiation, progression, and resistance to therapeutics in multiple types of neurogenic tumours. Targeted therapies for this mechanism have been designed and developed in preclinical and clinical studies, including selective TrkB inhibitors and pan‐TRK inhibitors. This review describes the gene structure, biological function, abnormal TrkB activation mechanism, and current‐related targeted therapies in neurogenic tumours.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
ORCID-Profile: Zhi-Chao Wang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Li, Y., Wei, C., Wang, W., Li, Q., & Wang, Z. C. (2023). Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours. The Journal of Pathology: Clinical Research, 9(2), 89-99. https://doi.org/10.1002/cjp2.307
Vancouver
Li Y, Wei C, Wang W, Li Q, Wang ZC. Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours. The Journal of Pathology: Clinical Research. 2023;9(2):89-99. doi:10.1002/cjp2.307
BibTeX
@article{Li2023,
author = {Li, Yuehua and Wei, Chengjiang and Wang, Wei and Li, Qingfeng and Wang, Zhi-Chao},
title = {Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours},
journal = {The Journal of Pathology: Clinical Research},
year = {2023},
volume = {9},
number = {2},
pages = {89--99},
doi = {10.1002/cjp2.307}
}
EUVIMED